Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Recipharm Subsidiary Files Infectious Disease Drug Application in European Markets

Published: Tuesday, December 17, 2013
Last Updated: Tuesday, December 17, 2013
Bookmark and Share
Drug product developed through partnership with Astimex Pharma.

RPH Pharmaceuticals AB has announced the filing of an application for an infectious disease drug product in a range of European countries.

The product has been developed through a partnership with Swedish pharmaceutical company, Astimex Pharma AB, which is set to market the product in the Nordic market.

As a "first in class generic", the product, owned by RPH Pharmaceuticals, will be licensed to third parties for distribution in markets where Astimex presently is not represented.

In addition to the filed application, Astimex and RPH Pharmaceuticals have expanded their collaboration with another manufacturing and development project in which the drug target is another first in class generic approved for use in most of the North European markets.

The collaboration represents joint investments where Recipharm builds a registration dossier, whilst Astimex takes full responsibility for sales and distribution in the Swedish market and RPH Pharmaceuticals can out-license sales and distribution rights in other markets.

Johan Åkerblom, Business Development Manager, RPH Pharmaceuticals commented: “We are delighted that the collaboration with Astimex is proving to be so successful for both our companies. Indeed, we are greatly excited by the pace at which drug products are being developed and licensing, sales and distribution arrangements are being set in place. Furthermore, the sales potential for the collaboration products looks very promising with the infectious disease target being one clear example of this.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Recipharm Reaches Agreement with LobSor Pharmaceuticals
Agreement to manufacture LECIGON™, a proprietary treatment for advanced Parkinson’s disease.
Thursday, September 10, 2015
Recipharm Signs Agreement with RedHill Biopharma
Agreement for manufacturing of RHB-105 for treatment of H. pylori infection.
Thursday, August 27, 2015
Recipharm Secures Additional Bank Financing for Continued Growth
Company has entered a new five-year SEK 1 500 million term loan facility with three of the largest banks.
Tuesday, July 14, 2015
Recipharm Invests SEK 8 Million in Pharmanest
Investment to support the development of Pharmanest’s lead drug candidate SHACT.
Friday, July 10, 2015
Recipharm Reduces Risk and Improves Compliance with Infor
Company will also help Recipharm continue to improve compliance with the EU-GMP code of practice.
Thursday, July 09, 2015
Recipharm Appoints New Sales Director, Development Services
Amine Tahiri has joined the Development Services Sales team with effect from 1 July 2015.
Tuesday, June 30, 2015
Recipharm Acquires OnTarget Chemistry
Company extends its offering into preclinical development services.
Tuesday, June 16, 2015
Recipharm Appoints Chief Strategy Officer
Company has appointed Jean-François Hilaire to the new position of CSO.
Thursday, June 04, 2015
Recipharm Signs Partnership Agreement with Follicum
Agreement in preparation for a clinical trial of the drug candidate FOL-005.
Thursday, June 04, 2015
Recipharm Appoints New General Manager
Appointment of Giorgio Bruno as General Manager of Recipharm Italia S.p.A.
Thursday, April 30, 2015
Recipharm is Commencing Negotiations with LIDDS
Collaboration on large-scale manufacture of Liproca® Depot.
Friday, April 24, 2015
Recipharm Makes Strategic Investment in Synthonics
Recipharm has purchased $2.0 million of preferred stock in the company.
Wednesday, April 15, 2015
Recipharm and Adroit Science Form Collaboration
Company will support Recipharm’s pharmaceutical development with high quality solid state characterization services.
Thursday, March 26, 2015
Recipharm Completes Korean Serialization Project for Abbott
Validation batches planned to be shipped to Korea mid-March 2015.
Thursday, March 19, 2015
Recipharm Appoints New Position of Vice President Quality Management
Appointment of Thomas Beck with effect from 1st April 2015.
Wednesday, March 11, 2015
Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos